Biocon founder Kiran Mazumdar Shaw says she is confident that the company’s investment and capacity expansion in Insulin will make the company the top hub for the drug in the next five years. She speaks in an exclusive conversation with Bloomberg’s Haslinda Amin. (Source: Bloomberg)
Trending
- More rail services in England set to slow as heatwave shrinks soil | Rail transport
- Barclays increases bonus pool by nearly 30% as calls grow for UK bank tax | Barclays
- Stocks making the biggest moves after hours: CDNS, RMBS, WELL
- CME launches single stock futures enabling investors to trade SpaceX, Micron and others 23 hours a day
- Nvidia’s potential new deal with OpenAI would revive a spooky tech-bubble habit, analyst warns
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
- Chipotle Mexican Grill’s Next Earnings Report on July 29 Could Send the Stock Sliding. Here’s Why.
- Stocks Settle Mixed as AI Angst Offsets Easing Geopolitical Tensions
Tuesday, July 28
